Crossref
CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer
Clinical Ovarian Cancer · 2011
DOI: 10.1016/j.cloc.2011.04.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Ovarian Cancer, 2011. Verfasst von Robert Mannel. Die Arbeit nennt 13 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
Mannel, R. (2011). CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer. Clinical Ovarian Cancer. https://doi.org/10.1016/j.cloc.2011.04.010
Vancouver
Mannel R. CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer. Clinical Ovarian Cancer. 2011. doi:10.1016/j.cloc.2011.04.010
BibTeX
@article{Mannel2011,
author = {Mannel, Robert},
title = {CON: Dose-dense Paclitaxel at 80 mg/m2 Weekly in Combination with Carboplatin AUC-6 Every Three Weeks Should Not be Considered Standard of Care in the Front Line Management of Ovarian Cancer},
journal = {Clinical Ovarian Cancer},
year = {2011},
doi = {10.1016/j.cloc.2011.04.010}
}
EUVIMED